Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
Carbamazepine, the active ingredient in Tegretol Tablets, can affect the body in several different ways. It is an anti-convulsant medicine (prevents fits), it can also modify some types of pain and can control mood disorders.
Tegretol is used:
Some people MUST NOT take Tegretol Tablets. Talk to your doctor if:
If any of these apply to you, do not take Tegretol and tell your doctor.
A small number of people being treated with anti-epileptics such as carbamazepine have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.
If an allergic reaction happens, such as swelling of lips, eyelids, face, throat, mouth, or sudden breathing problems, fever with lymph nodes swelling, rash or skin blistering, tell your doctor immediately or go to the emergency department at your nearest hospital (see “Possible side effects”).
Serious skin rashes (Stevens- Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of carbamazepine. Frequently, the rash can involve ulcers of the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These serious skin rashes are often preceded by influenza-like symptoms fever, headache, body ache (flu-like symptoms). The rash may progress to widespread blistering and peeling of the skin. The highest risk for occurrence of serious skin reactions is within the first months of treatment.
These serious skin reactions can be more common in people from some Asian countries. The risk of these reactions in patients of Han Chinese or Thai origin may be predicted by testing a blood sample of these patients. Your doctor should be able to advise if a blood test is necessary before taking carbamazepine.
If you develop a rash or these skin symptoms, stop taking carbamazepine and contact your doctor immediately.
If you experience dizziness, drowsiness, decrease in blood pressure, confusion, due to Tegretol treatment, this may lead to falls.
You should also ask yourself these questions before taking Tegretol Tablets. If the answer to any of these questions is YES, discuss your treatment with your doctor or pharmacist because Tegretol Tablets might not be the right medicine for you.
Because of the way that Tegretol works, it can affect, and be affected by, lots of other things that you might be eating or medicines that you are taking. It is very important to make sure that your doctor knows all about what else you are taking, including anything that you have bought from a chemist or health food shop. It may be necessary to change the dose of some medicines, or stop taking something altogether.
There is a risk of harm to the unborn child if Tegretol is used during pregnancy. Women of childbearing age should use effective contraception during treatment with Tegretol and for at least two weeks after the last dose (see the information in Section 2 on pregnancy and breastfeeding).
It is important to tell your doctor or pharmacist if you are taking any other medicines for epilepsy at the same time as carbamazepine and you are pregnant, think you may be pregnant, or are planning to have a baby (see the information in Section 2 on pregnancy and breastfeeding).
Tell the doctor if you are taking:
If you are a woman who is able to have a baby and are not planning a pregnancy, you should use effective contraception during treatment with Tegretol. Tegretol may affect how hormonal contraceptives, such as the contraceptive (birth control) pill, work and make them less effective at preventing pregnancy. Talk to your doctor, who will discuss with you the most suitable type of contraception to use while you are taking Tegretol. If treatment with Tegretol is discontinued you should continue using effective contraception for at least two more weeks following discontinuation.
If you are pregnant, or think you may be pregnant, you must tell your doctor straight away and discuss possible risks the epilepsy medicine you are taking might pose to your unborn baby.
If you are planning to become pregnant you should discuss your epilepsy treatment with your doctor as early as possible before you become pregnant.
You should not stop your treatment without discussing this with your doctor. Suddenly stopping may lead to breakthrough seizures which may harm you and your unborn baby. It is important that your epilepsy remains well controlled.
Taking carbamazepine during pregnancy increases the chance that the baby may have a physical birth abnormality (major congenital malformations). Studies with women treated with carbamazepine for epilepsy have shown that on average 4-5 babies in every 100 will have serious physical birth abnormalities. This is compared with 2 to 3 babies in every 100 born to women who do not have epilepsy.
These abnormalities can develop early in pregnancy, even before you know you are pregnant. The most common types of major congenital malformations reported for carbamazepine include spina bifida (where the bones of the spine are not properly developed); facial and skull malformations including cleft lip/palate; skeletal, heart, urinary tract and sexual organ malformations.
Studies have found that the risk of physical birth abnormalities increases with increasing doses of carbamazepine. Therefore, it is important that where possible you are prescribed the lowest dose to control your epilepsy.
Ask your doctor about taking folic acid when trying for a baby and during pregnancy. Folic acid may lower the general risk of serious physical birth abnormalities that exists with all pregnancies.
Taking more than one epilepsy medicine at the same time may also increase the risk of physical birth abnormalities. This means that where possible, your doctor should consider using only one epilepsy medicine to control your epilepsy.
Problems with neurodevelopment (development of the brain) cannot be ruled out in children born to women with epilepsy treated with carbamazepine alone or in combination with other antiepileptic drugs during pregnancy.
If you take Tegretol during pregnancy, your baby is also at risk for bleeding problems right after birth. Your doctor may give you and your baby a medicine to prevent this.
Mothers taking Tegretol Tablets can breastfeed their babies, but you must tell the doctor as soon as possible if you think that the baby is suffering side effects such as excessive sleepiness, skin reaction or yellow skin and eyes, dark urine or pale stools.
You should use an effective method of contraception throughout your treatment with Tegretol and for a period of 28 days after discontinuation of treatment. Irregularity of the menstrual period may occur in women taking hormonal contraceptives (birth control medicines) and Tegretol. The hormonal contraceptive may become less effective and you should consider using a different or additional non-hormonal contraceptive method. Ask your doctor about effective contraception.
Tegretol Tablets can make you feel dizzy or drowsy, or may cause blurred vision, double vision, or you may have a lack of muscular coordination, especially at the start of treatment or when the dose is changed. If you are affected in this way, or if your eyesight is affected, you should not drive or operate machinery.
This medicine contains less than 1mmol sodium (23mg) per tablet, that is to say essentially ‘sodium free’.
The doctor will tell you how many Tegretol Tablets to take and when to take them. Always follow his/her instructions carefully. The dose will be on the pharmacist’s label. Check the label carefully. It is important to take the tablets at the right times. If you are not sure, ask your doctor or pharmacist. Keep taking your tablets for as long as you have been told, unless you have any problems. In that case, check with your doctor.
Your doctor will usually start Tegretol at a fairly low dose which can then be increased to suit you individually. The dose needed varies between patients. You can take Tegretol Tablets during, after or between meals. Swallow the tablets with a drink. You are usually told to take a dose two or three times a day. If necessary you may break the tablets in half along the scored line.
Adults: 800-1,200 mg a day, although higher doses may be necessary. If you are elderly you might require a lower dose.
Aged 5-10 years: 400-600 mg a day
Aged 10-15 years: 600-1,000 mg a day.
Tegretol Tablets are not recommended for children under 5.
600-800 mg a day. The maximum dose is 1200mg a day. If you are elderly you might require a lower dose.
400-600 mg a day
If you forget to take a dose, take one as soon as you remember. If it is nearly time for your next dose, though, just take the next dose and forget about the one you missed.
If you accidentally take too many Tegretol Tablets, tell your doctor or your nearest hospital casualty department. Take your medicine pack with you so that people can see what you have taken.
Tegretol Tablets do not usually cause problems, but like all medicines, they can sometimes cause side effects.
Stop taking Tegretol Tablets and tell your doctor straight away if you notice:
Do not be alarmed by this list. Most people take Tegretol Tablets without any problems.
If any of the symptoms become troublesome, or if you notice anything else not mentioned here, please go and see your doctor. He/she may want to give you a different medicine.
There have been reports of bone disorders including osteopenia and osteoporosis (thinning of the bone) and fractures. Check with your doctor or pharmacist if you are on long-term antiepileptic medication, have a history of osteoporosis, or take steroids.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
The tablets come in three strengths containing either 100, 200 or 400 mg of the active ingredient carbamazepine. The tablets also contain the inactive ingredients silicon dioxide, microcrystalline cellulose, magnesium stearate and sodium carboxymethylcellulose.
Tegretol 100 Tablets are round, white tablets with one side impressed “GEIGY”, the other “B/W” and a score line.
Tegretol 200 Tablets are round, white tablets with one side impressed “CG”, the other “G/K” and a score line.
The 100 mg and 200 mg tablets come in blister packs of 84.
Tegretol 400 mg Tablets are rod-shaped, white tablets with CG/CG on one side and LR/LR on the other. Both sides have a score line.
The 400 mg tablets come in blister packs of 56.
Marketing Authorisation Holder: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom.
Manufacturer: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom and Novartis Farma S.p.A., Via Provinciale Schito. 131, 80058 Torre Annunziata (NA), Italy.
This leaflet was last revised in 11/2023.
If you would like any more information, or would like the leaflet in a different format, please contact Medical Information at Novartis Pharmaceuticals UK Ltd, telephone number 01276 698370.
TEGRETOL is a registered trade mark
Copyright Novartis Pharmaceuticals UK Limited
Full name: Tegretol 200 mg tablets
- Invented name part: Tegretol
- Scientific name part: Carbamazepine
- Strength part: 200 mg
- Pharmaceutical dose form part: tablets
Name usage: English (Spain)
Authorised dose form:
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: active
Product classification:
Marketing Authorisation 1 of 1
Authorisation number: 39.955
Region:
Marketing authorisation holder: Novartis Farmacéutica, S.A.
Identifier:
Status: Active (2018-06-21)
Package 1 of 1
PMSWI: 39.955
Description:
Marketing status:
Pack size:
Package: 1 Box (Cardboard)
Containing:
Package: 28 Blister (PolyVinyl Chloride)
Containing:
Manufactured Item
Dose form: Film-coated tablet
Unit of presentation: Tablet
Ingredient
Role: active
Substance: CARBAMAZEPINE
Ingredient
Role: Excipient
Substance: Magnesium stearate
Ingredient
Role: Excipient
Substance: CARBOXYMETHYLCELLULOSE
Administrable Product (1 of 1)
Dose form: tablet
Unit of presentation: tablet
Route of administration:
Ingredient
Role: active
Substance: CARBAMAZEPINE
Ingredient
Role: Excipient
Substance: Magnesium stearate
Ingredient
Role: Excipient
Substance: CARBOXYMETHYLCELLULOSE